Patents by Inventor Christopher G. THOMSON

Christopher G. THOMSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GCN2 MODULATING COMPOUNDS AND USES THEREOF
    Publication number: 20240150345
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).
    Type: Application
    Filed: January 21, 2022
    Publication date: May 9, 2024
    Inventors: Savithri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Benjamin Rahemtulla, Eric P.A. Talbot, Christopher G. Thomson
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20240140959
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 30, 2023
    Publication date: May 2, 2024
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James Anthony NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • GCN2 MODULATING COMPOUNDS AND USES THEREOF
    Publication number: 20240083897
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).
    Type: Application
    Filed: January 21, 2022
    Publication date: March 14, 2024
    Inventors: Savithiri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Benjamin Rahemtulla, Eric P.A. Talbot, Christopher G. Thomson
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11820778
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: November 21, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20230212139
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11548865
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20220411435
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: August 8, 2022
    Publication date: December 29, 2022
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11485742
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: November 1, 2022
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210130365
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 6, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210107889
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG